Peptide researchers looking to explore the similarities and differences between melanotan 1 vs. melanotan 2 have come to just the right place.
This comprehensive overview compares the two peptides, providing insights into their benefits, side effects, and applications.
Our expert team also provide details on the potential of melanotan 1 and melanotan 2 for uses like:
Buy Melanotan 1 from our top-rated vendor...
Disclaimer: Peptides.org contains information about products that are intended for laboratory and research use only, unless otherwise explicitly stated. This information, including any referenced scientific or clinical research, is made available for educational purposes only. Likewise, any published information relative to the dosing and administration of reference materials is made available strictly for reference and shall not be construed to encourage the self-administration or any human use of said reference materials. Peptides.org makes every effort to ensure that any information it shares complies with national and international standards for clinical trial information and is committed to the timely disclosure of the design and results of all interventional clinical studies for innovative treatments publicly available or that may be made available. However, research is not considered conclusive. Peptides.org makes no claims that any products referenced can cure, treat or prevent any conditions, including any conditions referenced on its website or in print materials.
Melanotan 1 (MT1), also known as [Nle4, D-Phe7]-alpha-MSH or afamelanotide (CUV1647), is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH).
Alpha-MSH is an endogenous 13 amino acid peptide that plays a pivotal role in regulating melanin synthesis, sexual desire, energy balance, and appetite. These functions are primarily mediated through the melanocortin receptors (MCRs) in various tissues.
The structure of MT1 closely resembles that of endogenous alpha-MSH. Here are some more specifics:
As an MC1R agonist, MT1 facilitates melanin production, leading to a darker skin tone with repeated administration.
Initially developed as a sunless tanning and photoprotective agent, MT1 has shown promise in therapeutic areas such as in treating acute photodermatoses, including erythropoietic protoporphyria and polymorphic light eruption.
In October 2019, the United States Food and Drug Administration (FDA) approved MT1 under the brand name Scenesse for increasing sunlight tolerance and alleviating pain from ultraviolet (UV) light exposure in patients with erythropoietic protoporphyria (EPP).
EPP is caused by enzyme deficiency, leading to a buildup of protoporphyrin IX in the skin and blood. Protoporphyrin IX can absorb UV light to create reactive oxygen species that damage skin and cause pain and scarring.
Scenesse is administered to EPP patients as subcutaneous implants, offering improved pharmacokinetics compared to regular injections.
In addition, MT1 is also available as a research peptide for scientific and educational purposes. In this manner, it is typically shipped in dry powder form for reconstitution and subcutaneous administration.
Melanotan 2 (MT2) is another synthetic analog of alpha-MSH, but it differs significantly from MT1 and alpha-MSH in terms of structure:
By targeting MC1R and MC4R, MT2 regulates melanogenesis and sexual behavior, respectively. It also interacts with MC3R, which is linked to metabolic regulation.
Originally developed as a tanning agent, ongoing research suggests additional clinical applications for MT2, including the management of erectile dysfunction in men.
MT2 is not currently approved for human use and remains the subject of active research for its various potential uses.
MT1 and MT2 have shown various potential benefits thanks to their action on the melanocortin receptors.
Below, we’ll outline some of the most notable benefits observed with both compounds.
Both MT1 and MT2 have been reported to stimulate MC1R for increased skin pigmentation:
While both peptides have been shown to cause sunless tanning, MT1 is considerably more selective towards the MC1R.
Thus, it has been investigated thoroughly as an agent for increasing tolerance to sunlight in several conditions:
The benefits of melanocortin agonists for libido and erectile function owe primarily to its activation of MC4R.
Thus, MT2 is considerably more effective for sexual function than MT1 and can boost sex drive in both males and females.
Here is some of the most notable research on melanotan 2 for sexual health:
MT1 and MT2 may also provide additional benefits related to their structure and melanocortin receptor affinity, including:
Overall, MT1 appears to be more thoroughly studied regarding potential side effects after short-term and long-term application.
Moreover, the peptide is already approved for human use by the FDA in the form of subcutaneous implants. Nevertheless, MT1 is not free of adverse reactions and risks.
Here are more details on the potential side effects of MT1:
Conversely, findings on the safety profile of MT2 are primarily based on short-term studies. Notable findings include:
Both MT1 and MT2 are contraindicated in subjects who are pregnant, breastfeeding, under 18 years of age, or who have a prior history of skin-related malignancies.
MT1 and MT2 exhibit numerous differences in terms of molecular structure, receptor binding affinity, potential side effects, dosage, and regulatory status.
Therefore, there are multiple factors to consider when outlining the biggest differences between the two melanocortin agonists:
This structural variance significantly affects their interaction with melanocortin receptors in the body, thereby influencing their potential therapeutic impact and side effects.
